IGF1R and McLeod neuroacanthocytosis syndrome: In addition, FUS–DDIT3 induces activation of IGF-IR and PI3K/AKT signaling, and therapies targeting IGF-IR have shown efficacy in treating MLS both in vitro and in vivo.